E A Perez

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint HER2 testing: current status and future directions
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA Electronic address
    Cancer Treat Rev 40:276-84. 2014
  2. pmc RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA
    Breast Cancer Res Treat 138:427-35. 2013
  3. pmc Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples
    Douglas W Mahoney
    Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    BMC Res Notes 6:33. 2013
  4. pmc Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 31:2115-22. 2013
  5. doi request reprint Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Sara A Hurvitz
    University of California, Los Angeles Jonsson Comprehensive Cancer Center and Translational Oncology Research International, Los Angeles, CA, USA
    J Clin Oncol 31:1157-63. 2013
  6. pmc Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 138:99-108. 2013
  7. pmc Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer
    Luigi Strizzi
    Children s Memorial Research Center, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 2300 Children s Plaza, Chicago, IL 60614, USA
    Breast Cancer Res 14:R75. 2012
  8. doi request reprint Current and emerging targeted therapies for metastatic breast cancer
    Edith A Perez
    Division of Hematology and Oncology, College of Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA
    Cancer 118:3014-25. 2012
  9. pmc Treatment options for patients with triple-negative breast cancer
    Rafael Santana-Davila
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida, 32224, USA
    J Hematol Oncol 3:42. 2010
  10. pmc Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform
    Monica M Reinholz
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA
    BMC Med Genomics 3:60. 2010

Detail Information

Publications105 found, 100 shown here

  1. doi request reprint HER2 testing: current status and future directions
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA Electronic address
    Cancer Treat Rev 40:276-84. 2014
    ..Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status...
  2. pmc RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA
    Breast Cancer Res Treat 138:427-35. 2013
    ..The addition of lapatinib to paclitaxel and trastuzumab following AC does not add cardiac toxicity. Lapatinib dose of 750 mg/day in combination with standard chemotherapy plus trastuzumab has acceptable overall tolerability...
  3. pmc Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples
    Douglas W Mahoney
    Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    BMC Res Notes 6:33. 2013
    ....
  4. pmc Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 31:2115-22. 2013
    ....
  5. doi request reprint Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Sara A Hurvitz
    University of California, Los Angeles Jonsson Comprehensive Cancer Center and Translational Oncology Research International, Los Angeles, CA, USA
    J Clin Oncol 31:1157-63. 2013
    ....
  6. pmc Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 138:99-108. 2013
    ..Agreement was improved at adjudication (96 %). HER2 tumor heterogeneity appears to partially explain discordant results in cases initially tested as positive and subsequently called negative...
  7. pmc Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer
    Luigi Strizzi
    Children s Memorial Research Center, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 2300 Children s Plaza, Chicago, IL 60614, USA
    Breast Cancer Res 14:R75. 2012
    ....
  8. doi request reprint Current and emerging targeted therapies for metastatic breast cancer
    Edith A Perez
    Division of Hematology and Oncology, College of Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA
    Cancer 118:3014-25. 2012
    ..These agents as well as other novel classes of anticancer agents are being tested in clinical trials with the potential of addressing unmet therapeutic needs in the MBC patient population...
  9. pmc Treatment options for patients with triple-negative breast cancer
    Rafael Santana-Davila
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida, 32224, USA
    J Hematol Oncol 3:42. 2010
    ..Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease...
  10. pmc Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform
    Monica M Reinholz
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA
    BMC Med Genomics 3:60. 2010
    ..5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors...
  11. pmc 3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer
    Yan W Asmann
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    BMC Genomics 10:531. 2009
    ..In this preliminary effort, we evaluated the 3' DGE approach using two reference RNA samples from the MicroArray Quality Control Consortium (MAQC)...
  12. ncbi request reprint A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Oncology 69:117-21. 2005
    ..A phase II multi-institutional clinical trial conducted to evaluate the efficacy and tolerability of docetaxel and carboplatin as first-line therapy for women with metastatic breast cancer...
  13. ncbi request reprint Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
    Edith A Perez
    Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 25:3407-14. 2007
    ..To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study...
  14. ncbi request reprint Novel enhanced delivery taxanes: an update
    Edith A Perez
    Mayo School of Medicine, Jacksonville, FL 32224, USA
    Semin Oncol 34:suppl 1-5. 2007
    ....
  15. ncbi request reprint Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer
    Alvaro Moreno-Aspitia
    Mayo Clinic, Jacksonville, FL 32224, USA
    Future Oncol 1:755-62. 2005
    ....
  16. ncbi request reprint Appraising adjuvant aromatase inhibitor therapy
    Edith A Perez
    Mayo Clinic, Jacksonville, Florida 32224, USA
    Oncologist 11:1058-69. 2006
    ..The anticipated results of ongoing trials will provide further insights into the long-term safety and application of AI therapy in the adjuvant setting...
  17. pmc Aromatase inhibitors and bone loss
    Edith A Perez
    Divison of Hematology Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Oncology (Williston Park) 20:1029-39; discussion 1039-40, 1042, 1048. 2006
    ..These safety concerns should be balanced with the potential of bisphosphonates to minimize or prevent the debilitating effects of AI-associated bone loss in patients with early, hormone receptor-positive breast cancer...
  18. ncbi request reprint Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
    ..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen...
  19. ncbi request reprint HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 24:3032-8. 2006
    ..To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab...
  20. doi request reprint Breast cancer management: opportunities and barriers to an individualized approach
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Oncologist 16:20-2. 2011
    ..The current issues facing the delivery of individualized breast cancer care will be the focus of this discussion...
  21. ncbi request reprint Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    Clin Breast Cancer 6:425-32. 2005
    ..The efficacy and tolerability of 2 different schedules of paclitaxel/carboplatin/trastuzumab for HER2-overexpressing metastatic breast cancer (MBC) were evaluated in this parallel multicenter phase II trial...
  22. ncbi request reprint Phase II trial of dolastatin-10 in patients with advanced breast cancer
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Invest New Drugs 23:257-61. 2005
    ..Phase II multicenter cooperative group study investigated the efficacy and toxicity of the novel anti-microtubule agent dolastatin-10 in patients with advanced breast cancer...
  23. ncbi request reprint Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
    E A Perez
    Mayo Clinic, Jacksonville, FL, USA
    Ann Oncol 18:viii26-35. 2007
    ....
  24. pmc Safety of aromatase inhibitors in the adjuvant setting
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 105:75-89. 2007
    ..Overall, the benefits of AIs over tamoxifen are achieved without compromising overall quality of life...
  25. doi request reprint Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  26. pmc Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Natl Cancer Inst 104:159-62. 2012
    ..We recommend using FDA-approved HER2 criteria for therapeutic decision making...
  27. pmc Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 29:4491-7. 2011
    ....
  28. pmc Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 29:3366-73. 2011
    ..Long-term follow-up results on disease-free survival (DFS) and overall survival (OS) have been awaited...
  29. pmc HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial
    Edith A Perez
    Serene M and Frances C Durling Professor of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 28:4307-15. 2010
    ....
  30. doi request reprint Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Edith A Perez
    Division of Hematology and Oncology, College of Medicien, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 121:261-71. 2010
    ....
  31. ncbi request reprint Adjuvant therapy of triple negative breast cancer
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 120:285-91. 2010
    ....
  32. pmc North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
    E A Perez
    Multidisciplinary Breast Clinic and Breast Cancer Program, Mayo Clinic, Jacksonville, FL 32224, USA
    Ann Oncol 21:269-74. 2010
    ..This study was conducted to assess the safety and efficacy of TX-BV in patients with MBC...
  33. doi request reprint Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
    Edith A Perez
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL32224, USA
    Mol Cancer Ther 8:2086-95. 2009
    ..This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents...
  34. ncbi request reprint Cardiac toxicity of ErbB2-targeted therapies: what do we know?
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Clin Breast Cancer 8:S114-20. 2008
    ....
  35. doi request reprint Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    Mayo Clin Proc 83:679-86. 2008
    ..To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR (ERBB1) and HER2 inhibitor, using prospective data collected in 44 clinical studies...
  36. doi request reprint Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer
    Edith A Perez
    Division of Hematology Oncology, Mayo College of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 114:195-201. 2009
    ..Development of new agents and identification of genetic biomarkers in translational studies promise to improve management of patients with resistant/refractory breast cancer...
  37. ncbi request reprint Management recommendations for adjuvant systemic breast cancer therapy
    Edith A Perez
    Multidisciplinary Breast Clinic and Division of Hematology Oncology, Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    Breast Dis 21:15-21. 2004
  38. ncbi request reprint Carboplatin in combination therapy for metastatic breast cancer
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32224, USA
    Oncologist 9:518-27. 2004
    ..Preclinical studies have demonstrated synergistic antitumor efficacy of carboplatin and trastuzumab in HER2(+) models...
  39. ncbi request reprint Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?
    Edith A Perez
    Division of Hematology and Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Curr Oncol Rep 5:66-71. 2003
    ..Such ongoing studies as NSABP B-30 will be instrumental in establishing the relative merits of sequential versus concurrent taxane-anthracycline adjuvant regimens for patients with node-positive breast cancer...
  40. ncbi request reprint Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations
    E A Perez
    Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA
    Cancer Invest 19:155-64. 2001
    ..Therapy can be continued with single-agent paclitaxel. In order to minimize cardiac risk, patients should be selected carefully and be monitored for adverse cardiac effects...
  41. ncbi request reprint Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Clin Oncol 22:2849-55. 2004
    ..Previous clinical trials suggested that irinotecan might have such activity. We conducted this multicenter phase II study to assess efficacy and tolerability of two irinotecan schedules...
  42. ncbi request reprint Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Cancer Invest 21:1-6. 2003
    ..Tamoxifen has been reported to enhance the antitumor activity of cisplatin in preclinical models by modulation of protein kinase C signal transduction and apoptosis-related pathways...
  43. ncbi request reprint Adjuvant therapy trials of radiotherapy and systemic treatment for breast cancer
    Betty A Mincey
    Division of Hematology Oncology, Mayo Clinic and Foundation, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Curr Oncol Rep 4:1. 2002
  44. ncbi request reprint Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    Lung Cancer 44:347-53. 2004
    ..This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC...
  45. ncbi request reprint Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Clin Breast Cancer 4:S113-6. 2004
    ..In addition, several phase II trials have suggested that this combination is feasible and active in patients who have received prior anthracycline and/or taxane therapy...
  46. ncbi request reprint Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer
    E A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Clin Oncol 19:4216-23. 2001
    ..Entry criteria were relatively liberal to reflect the heterogeneity of metastatic breast cancer in clinical practice...
  47. ncbi request reprint Clinical cardiac tolerability of trastuzumab
    Edith A Perez
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 22:322-9. 2004
    ....
  48. ncbi request reprint Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
    Edith A Perez
    North Central Cancer Treatment Group, Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 22:3700-4. 2004
    ....
  49. ncbi request reprint Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer
    E A Perez
    Mayo Clinic, Jacksonville, Florida 32224, USA
    Clin Breast Cancer 1:S52-6. 2000
    ....
  50. ncbi request reprint Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study
    E A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 16:754-60. 1998
    ..The antiemetic effectiveness and safety of single-dose oral granisetron were compared with intravenous (I.V.) ondansetron in chemotherapy-naive patients who received moderately emetogenic chemotherapy...
  51. ncbi request reprint Weekly paclitaxel in women age 65 and above with metastatic breast cancer
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Breast Cancer Res Treat 73:85-8. 2002
    ..Response rates and overall survival times were comparable in the two age groups (<65 and > or =65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer...
  52. ncbi request reprint Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review
    E A Perez
    Division of Hematology Oncology and Mayo Foundation, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Support Care Cancer 7:413-24. 1999
    ..A number of recent investigations suggest that appropriate doses of 5-HT(3) receptor antagonists with phenothiazine and corticosteroids can improve the safety and efficacy of antiemetic regimens in patients undergoing transplantation...
  53. ncbi request reprint 5-HT3 antiemetic therapy for patients with breast cancer
    E A Perez
    Division of Hematology Oncology, Mayo Foundation and Mayo Clinic Jacksonville, Florida 32224, USA
    Breast Cancer Res Treat 57:207-14. 1999
    ..The most recent clinical studies demonstrate that 5-HT3 antagonists can significantly reduce the incidence of nausea in breast cancer patients receiving moderately emetogenic chemotherapy and should be employed in this setting...
  54. ncbi request reprint A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
    E A Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Ann Oncol 13:1225-35. 2002
    ....
  55. ncbi request reprint The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies
    E A Perez
    Division of Hematology Oncology, Mayo Clinic and Mayo Foundation, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Curr Oncol Rep 3:516-22. 2001
    ....
  56. doi request reprint Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
    J N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 19:877-82. 2008
    ..57, P = 0.00008]. The trial was unblinded and placebo patients were offered letrozole...
  57. ncbi request reprint Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study
    M Baweja
    Mayo Clinic, Jacksonville, FL 32224, USA
    Ann Oncol 17:623-9. 2006
    ..A one-stage phase II trial was conducted to assess the tumor response rate and toxicity profile of single agent oral vinorelbine as first or second-line chemotherapy for women at least 65 years of age with metastatic breast cancer...
  58. ncbi request reprint Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
    J N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 5:1642-9. 1999
    ..Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus letrozole was less than expected...
  59. doi request reprint Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer
    S L Hines
    Division of General Internal Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Ann Oncol 19:1561-5. 2008
    ..Relative survival of women with TN breast cancer who develop brain metastases is unknown...
  60. doi request reprint N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
    W W Tan
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Ann Oncol 21:493-7. 2010
    ..Because of the single-agent activity of irinotecan hydrochloride, combination of irinotecan and docetaxel treatment against metastatic breast cancer (MBC) should be evaluated...
  61. ncbi request reprint Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen
    P J Hesketh
    Division of Hematology Oncology, St Elizabeth s Medical Center, Boston, MA 02135 2907, USA
    Support Care Cancer 8:46-8. 2000
    ..Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed...
  62. ncbi request reprint A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
    C X Ma
    Mayo Clinic and Foundation, Department of Oncology and Medicine, Rochester, MN 55905, USA
    Ann Oncol 17:226-31. 2006
    ..This phase II study was undertaken to define the efficacy and toxicity of pemetrexed in combination with gemcitabine in patients with metastatic breast cancer...
  63. pmc N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial
    W W Tan
    Division of Hematology Oncology, Mayo Clinic, Jacksonville
    Ann Oncol 24:2548-54. 2013
    ..We conducted a phase II study of fulvestrant and bevacizumab in patients with aromatase inhibitor pretreated metastatic breast cancer...
  64. ncbi request reprint Role of axillary node dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience
    B A Mincey
    Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA
    Arch Surg 136:779-82. 2001
    ..T1b tumors should be managed with routine analysis of axillary lymph node status. Whether sentinel node mapping can change this standard awaits further study...
  65. pmc A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
    K D Miller
    Department of Medicine, Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
    Ann Oncol 23:331-7. 2012
    ..E2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor to a definitive randomized phase III trial...
  66. ncbi request reprint Breast cancer prevention trials
    D J Rhodes
    Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 2:558-65. 2000
    ..Until the results of this trial are available, it is premature to use raloxifene for primary breast cancer prevention...
  67. ncbi request reprint A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women
    A T Baron
    Tumor Biology Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 10:1175-85. 2001
    ..Furthermore, these data demonstrate that gender, age, menstrual cycle phase, menopausal status, and exogenous hormone use must be considered when using serum p110 sErbB1 concentrations as cancer biomarkers...
  68. ncbi request reprint Metastatic bone disease in breast cancer: the patient's perspective
    E A Perez
    Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Semin Oncol 28:60-3. 2001
    ....
  69. ncbi request reprint Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
    C L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 16:2377-81. 1998
    ..Anecdotal information suggested a low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem...
  70. ncbi request reprint Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
    P N Lara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento 95817, USA
    Cancer Chemother Pharmacol 48:22-8. 2001
    ..In view of these findings, we hypothesized that toremifene would reverse platinum resistance and that this interaction would be influenced by tumor estrogen receptor (ER) status...
  71. ncbi request reprint Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials
    Betty A Mincey
    Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA
    Oncologist 7:246-50. 2002
    ..The improved survival rate is due, at least in part, to the use of adjuvant systemic therapy. Ongoing studies are evaluating targeted therapies, with the potential of remarkably improving patient outcome...
  72. ncbi request reprint Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007
    Mark Pegram
    Clin Breast Cancer 8:S131-41. 2008
  73. pmc Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Bryan P Schneider
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 26:4672-8. 2008
    ..Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer...
  74. ncbi request reprint HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Mayo Clin Proc 77:148-54. 2002
    ..To evaluate amplification of the HER-2/neu gene by fluorescence ir situ hybridization (FISH) in tumors with weakly positive (2+) immunohistochemical staining...
  75. ncbi request reprint Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    Patrick C Roche
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Natl Cancer Inst 94:855-7. 2002
    ..The concordance for central HercepTest and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831...
  76. ncbi request reprint Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer
    Alexandru Eniu
    Cancer Institute, Ion Chiricuta Cluj Napoca, Romania
    Oncologist 10:665-85. 2005
    ..Weekly docetaxel and paclitaxel regimens represent valuable therapeutic options for women with metastatic breast cancer and have entered evaluation as part of adjuvant therapy for this disease...
  77. ncbi request reprint Molecularly targeted therapies for breast cancer
    Timothy J Hobday
    Department of Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Cancer Control 12:73-81. 2005
    ....
  78. pmc Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    Lori J Goldstein
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:4092-9. 2008
    ..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer...
  79. doi request reprint HER2-positive breast cancer: current treatment strategies
    Edith A Perez
    Mayo Clinic, Jacksonville, Florida, USA
    Cancer Invest 26:545-52. 2008
  80. ncbi request reprint Advances in adjuvant therapy for breast cancer
    Dennis J Slamon
    Division of Hematology Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
    ..Finally, new targeted agents are being investigated and ongoing research aims to identify additional potential therapeutic targets to further improve outcomes for these patients...
  81. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  82. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  83. ncbi request reprint NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
    Robert W Carlson
    Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 4:S1-26. 2006
    ..This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting...
  84. ncbi request reprint North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Clin Breast Cancer 6:361-4. 2005
  85. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  86. ncbi request reprint Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  87. ncbi request reprint TAC--a new standard in adjuvant therapy for breast cancer?
    Edith A Perez
    N Engl J Med 352:2346-8. 2005
  88. ncbi request reprint Improving patient care through molecular diagnostics
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    Semin Oncol 31:14-20. 2004
    ..The use of these systems will allow further development of customized therapies directed toward the particular molecular defects in a given cancer...
  89. ncbi request reprint Future options with trastuzumab for primary systemic and adjuvant therapy
    Jose Baselga
    Vall d Hebron University, Barcelona, Spain
    Semin Oncol 31:51-7. 2004
    ..Together, this extensive program, which includes analysis of predictive molecular and pathologic makers, will establish the efficacy, safety, and role of trastuzumab in early breast cancer...
  90. ncbi request reprint Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole
    Jacqueline M Lafky
    Tumor Biology Program, Cancer Center Statistics Unit, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    Cancer Res 65:3059-62. 2005
    ....
  91. ncbi request reprint Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer
    Jose Baselga
    Vall d Hebron University Hospital, Oncology Service, Barcelona, Spain
    Oncologist 11:4-12. 2006
    ..Overall, results from clinical trials are sufficiently compelling to consider 1 year of adjuvant trastuzumab treatment for women with HER-2-positive EBC based on the risk:benefit ratio demonstrated in these studies...
  92. ncbi request reprint Recent advances in adjuvant therapy for breast cancer
    Frances M Palmieri
    Mayo Clinic, Jacksonville, FL, USA
    Semin Oncol Nurs 19:10-6. 2003
    ..Studies reviewed evaluate the role of aromatase inhibitors, incorporation of taxanes into chemotherapy regimens, novel dosage schedules, and supportive care with epoetin alfa...
  93. ncbi request reprint Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
    Adam Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15123, USA
    J Clin Oncol 25:829-36. 2007
    ..The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss...
  94. ncbi request reprint Phase I trial of edatrexate in advanced breast and other cancers
    Philip Kuriakose
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Cancer Invest 20:473-9. 2002
    ..We feel that the biweekly EDX schedule is a tolerable regimen, which allows a higher dose intensity than weekly administration, and that EDX is an active agent for the treatment of patients with metastatic cancer...
  95. doi request reprint Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
    Adam Brufsky
    Magee Womens Hospital, Pittsburgh, Pennsylvania 15123, USA
    Oncologist 13:503-14. 2008
    ....
  96. ncbi request reprint Gemcitabine and targeted therapy in metastatic breast cancer
    Guangzhi Qu
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Semin Oncol 29:44-52. 2002
    ..In this review we summarize current available data of gemcitabine in the management of metastatic breast cancer, and provide a perspective of gemcitabine in future clinical research for management of this disease...
  97. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
    ..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...
  98. doi request reprint Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  99. ncbi request reprint Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  100. ncbi request reprint Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Surabhi Amar
    Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 109:1-7. 2008
    ..Ongoing trials designed to maximize the therapeutic ratio of these agents, are also discussed...
  101. ncbi request reprint Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....

Research Grants3

  1. Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial
    Edith Perez; Fiscal Year: 2009
    ..Our study proposes biomarker tissue correlative studies to help identify those patients most likely to benefit from this treatment. ..
  2. Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial
    MONICA MADDEN REINHOLZ; Fiscal Year: 2010
    ..Our study proposes biomarker tissue correlative studies to help identify those patients most likely to benefit from this treatment. ..